Project Sigma: Wellcome Funding For Scientific Research
This article was originally published in Start Up
The Wellcome Trust, the UK’s largest private funder of biomedical research, has hired industry veterans to run a new £200 million evergreen fund that will take full ownership of biotech start-ups and hold them with more patience than VCs can afford.
You may also be interested in...
Forma Therapeutics Inc.'s licensing agreement with Genentech Inc., announced June 27, is a creative twist on option-style dealmaking that could bring returns to the start-up's venture investors while skirting the traditional exit routes of acquisition and public offering. The deal illustrates one path highly innovative platform-focused biotechs could take when they are trying to satisfy the demands of venture backers while remaining focused on their strengths in early stage drug discovery.
As executives and investors scramble to find business models that more closely link investment and return, a handful of technology firms have alit on variations of a capital-efficient strategy: let someone else do the development dirty work.
Investments for start-ups seeking their first infusion of venture capital continues to be scarce as venture firms seek later-stage opportunities and liquidity to improve their own chances of raising new funds.